ストックスクリーナーアプリを入手
10.26
80.27%
-41.73
アフターアワーズ：
10.45
0.19
+1.85%
前日終値:
$51.99
開ける：
$10.2
24時間の取引高:
12,907
Relative Volume:
66.00
時価総額：
$3.64B
収益：
-
当期純損益:
-
株価収益率:
-5.4286
EPS:
-1.89
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-80.27%
1か月 パフォーマンス:
-80.27%
6か月 パフォーマンス:
-80.27%
1年 パフォーマンス:
-80.27%
1日の値動き範囲:
$10.07
$10.32
1週間の範囲:
$10.07
$10.32
52週間の値動き範囲:
$10.07
$10.32
ChemoCentryx, Inc. Stock (CCXI) Company Profile
Compare CCXI vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CCXI
ChemoCentryx, Inc.
|
10.26 | 3.64B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.87 | 121.26B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.28 | 83.04B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
828.24 | 50.22B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.00 | 43.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
348.85 | 39.16B | 4.98B | 69.60M | 525.67M | 0.5198 |
ChemoCentryx, Inc. Stock (CCXI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-10-11 | アップグレード | JP Morgan | Underweight → Neutral |
| 2021-10-11 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2021-10-08 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-10-08 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2021-07-07 | アップグレード | Stifel | Hold → Buy |
| 2021-05-07 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2021-05-07 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-05-07 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2021-05-07 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2021-05-07 | ダウングレード | Stifel | Buy → Hold |
| 2021-03-02 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-03-02 | 開始されました | Stifel | Buy |
| 2020-10-29 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-06-17 | 開始されました | BTIG Research | Buy |
| 2020-05-27 | 開始されました | Wells Fargo | Overweight |
| 2020-05-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-01-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-11-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-11-26 | 繰り返されました | Piper Jaffray | Overweight |
| 2019-03-27 | アップグレード | B. Riley FBR | Neutral → Buy |
| 2019-02-11 | 開始されました | Piper Jaffray | Overweight |
| 2018-09-07 | 開始されました | B. Riley FBR | Neutral |
| 2018-08-14 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-06-28 | 開始されました | Raymond James | Strong Buy |
| 2018-05-02 | 開始されました | H.C. Wainwright | Buy |
| 2017-02-21 | 開始されました | JMP Securities | Mkt Outperform |
| 2015-05-18 | アップグレード | JP Morgan | Neutral → Overweight |
| 2013-05-20 | 繰り返されました | Stifel | Buy |
| 2012-11-14 | 開始されました | Stifel Nicolaus | Buy |
すべてを表示
ChemoCentryx, Inc. (CCXI) 最新ニュース
US FDA Review Team Split On Amgen’s Tavneos Years Before Withdrawal Request - Citeline News & Insights
Asking Amgen to withdraw Tavneos, FDA revisits years-old data issue - BioCentury
Amgen thumbs-down on FDA’s ask, Tavneos sales continue - BioWorld MedTech
Amgen resists FDA request to pull rare disease drug Tavneos from the market - Fierce Pharma
Amgen’s Revenue Gains Outweigh News That FDA Wants Tavneos Pulled From Market - Citeline News & Insights
Amgen Defends Tavneos Benefit-Risk Profile Following FDA Withdrawal Request - Medical Professionals Reference
US FDA Wants Tavneos Pulled From Market, Amgen Declines - Citeline News & Insights
EMA reviewing Amgen’s vasculitis drug over trial ‘data integrity’ - BioWorld MedTech
Shareholder Alert: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Securities Fraud Class Action Lawsuit Filed Against ChemoCentryx, Inc. - Newsfile
Anca Vasculitis Drug Market Set for Dynamic Rise with Key Players ChemoCentryx, Inc. and Vifor Pharma - openPR.com
ChemoCentryx Target of Unusually High Options Trading (NASDAQ:CCXI) - 富途牛牛
Immuneering Appoints Dr. Thomas Schall as Chairman of the Board - The Globe and Mail
Biotech Premarket Movers: ChemoCentryx, Jazz, Ionis, Zogenix - TheStreet
Nephrotic Syndrome Pipeline Analysis, 2025 by DelveInsight | GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers Squibb, ChemoCentryx, SynAct Pharm - Barchart.com
Latham-Backed Drug Developer's Statements Can't Be Proven False, N.D. Cal. Judge Finds - Law.com
Amgen's ChemoCentryx prevails in investor lawsuit centered on autoimmune drug Tavneos - Fierce Pharma
Pharma Company Beats Investor Suit Over Drug Safety Claims - Law360
ANCA Vasculitis Pipeline 2025: Therapies, MOA Insights, And Key Clinical Trial Updates By Delveinsight By Delveinsight Vifor Pharma, Glaxosmithkline, Amgen, Genentech, Pfizer, Chemocentryx, Biogen - Menafn
Doctored data, protest from trial observers: Lawsuit points to alleged misconduct at Amgen-bought biotech - Fierce Pharma
Buy These 3 Cheap Stocks Now - The Globe and Mail
Kodiak Copper: Supporting the Copper Demand for the AI Revolution - The Globe and Mail
Palantir Stock Hits ATH, But Can the Rally Hold Without Volume? - The Globe and Mail
25-Year Pharma Veteran Joins aTyr to Launch First New Sarcoidosis Treatment in 70 Years - Stock Titan
Navigator Medicines Appoints Tausif ‘Tosh’ Butt as Chief Executive Officer and Khurem Farooq as Chairman of the Board of Directors - Business Wire
BeiGene Enters Sublease Agreement with ChemoCentryx for Expansion - TipRanks
Bernstein Litowitz Berger & Grossmann LLP Announces Notice of Pendency of Class Action for All Persons and Entities Who Purchased or Otherwise Acquired the Common Stock of ChemoCentryx, Inc. from November 26, 2019 through May 6, 2021, inclusive - Olean Times Herald
AMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATA - Finansavisen
Microscopic Polyangiitis (MPA) Treatment Industry to Witness - openPR.com
Amgen opts to sublease Peninsula space taken in $3.9 billion buyout - The Business Journals
ChemoCentryx (NASDAQ:CCXI) Sees Strong Trading Volume on Analyst Upgrade - 富途牛牛
RA Capital sues ChemoCentryx after biotech company's $3.9 billion sale to Amgen - The Business Journals
About Us | Laser Focus WorldImmuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors - FinancialContent
Amgen sees rare diseases as ‘fourth pillar’ of growth, driven by pair of 2022 deals - BioCentury
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market Foresees Noteworthy US$4.89 Billion Va - PharmiWeb.com
Focal Segmental Glomerulosclerosis Market to Observe Impressive Growth by 2032, Predicts DelveInsight | Leading CompaniesACELYRIN, Genentech, ChemoCentryx, Travere Therapeutics, Boehringer Ingelheim, Chinook Therapeutics - PR Newswire
Chemocentryx presents new chemokine CXCR6 receptor antagonists - BioWorld MedTech
Member Spotlight: Q&A with Catailyst - Massachusetts Biotechnology Council
Tausif ('Tosh') Butt to Join Idorsia Pharmaceuticals U.S. as President and General Manager - PR Newswire
Northwest Healthcare REIT: Stocks Analysts Recently Downgraded on TSX (NWH-UN) - The Globe and Mail
Chemocentryx discovers new CCR6 antagonists - BioWorld MedTech
Celldex Therapeutics Appoints Rita Jain, M.D. to Board of Directors - citybiz
All Eyes On Amjevita, Amgen’s Humira Biosimilar And Sole 2023 Product Launch - insights.citeline.com
The top 10 biopharma M&A deals of 2022 - Fierce Pharma
Humble & Fume Announces Chief Executive Officer (CEO) Transition - The Globe and Mail
Provention Bio onboards Rita Jain, M.D., to Board of Directors - World Business Outlook
Provention Bio Appoints Rita Jain, M.D., to Board of Directors - citybiz
Special Report: Year in ReviewDespite Market Woes, Billions of Dollars in Local Deals Still Went Through - Los Angeles Business Journal
Horizon Therapeutics is up for grabs; Sanofi and Amgen are ready to use cash for bids. - Medical Marketing and Media
Horizon Therapeutics fields buyout interest from Amgen, J&J and Sanofi - Reuters
Amgen’s Latest Acquisition Puts a Spotlight on Rare Autoimmune Disease - Amgen
Amgen Does Not Expect Big Enbrel Price Impact From US Humira Biosimilar Launches - Citeline News & Insights
ChemoCentryx, Inc. (CCXI) 財務データ
ChemoCentryx, Inc. (CCXI) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
0.10%
7.16%
大文字化:
|
ボリューム (24 時間):